The U.S. Food and Drug Administration awarded the inaugural round of Commissioner’s National Priority Vouchers (CNPVs), selecting nine products from a mix of investigational drugs, approved-abroad therapies and generics. The agency’s list includes programs from Disc Medicine and other companies that could qualify for a regulatory decision in as little as one to two months. BioCentury and MedCity News reported the awards and early market reaction, including a notable share move for Disc Medicine after its bitopertin NDA submission. Companies named by the FDA gain access to a compressed review timeline contingent on meeting the program’s criteria—products that address national priorities such as unmet medical need or domestic manufacturing. For select recipients, the CNPV designation is layered on top of existing expedited pathways and could materially accelerate commercial timelines and cash-flow planning. The pilot underscores the agency’s operational flexibility and has already influenced trading in affected small-cap biotechs. Clarification: the Commissioner’s National Priority Voucher (CNPV) pilot lets the FDA prioritize review slots for products deemed to address a national priority, shortening the review clock to roughly 30–60 days under program rules.